Top

Current Infectious Disease Reports

Published in:

26-02-2024 | Fluconazole | HOT TOPIC

Exploring the Potential of Farnesol as a Novel Antifungal Drug and Related Challenges

Authors: Dongming Zheng, Linlan Yang, Yuxin Bai, Jiangyan Yong, Yan Li

Published in: Current Infectious Disease Reports | Issue 4/2024

Abstract

Purpose of Review

Farnesol (FOH) is a quorum-sensing molecule with potential as an antifungal drug. Given the growing concern about fungal drug resistance, exploring new solutions is crucial. Therefore, summarizing the antifungal activity of FOH is expected to be the basis for further FOH research and application. Herein, we reviewed the in vitro and in vivo antifungal efficacy of FOH alone and in combination with conventional antifungal drugs, as well as its mechanisms of action. Furthermore, we discussed the prospects and challenges of the FOH application in detail.

Recent Findings

Recent studies have revealed that FOH can target various aspects, such as reactive oxygen species production, induction of apoptosis, and modulation of virulence factors, to inhibit fungal growth and reduce fungal pathogenicity, thereby exerting its antifungal activity. Furthermore, FOH can suppress resistance-associated genes, such as those of biofilm and ergosterol, so as to enhance the fungicidal effectiveness of conventional antifungal drugs. However, the action mechanism of FOH on drug efflux pumps remains unclear and warrants further investigation.

Summary

FOH can prevent and treat fungal infections. It exerts significant antimicrobial effects on fungal planktonic and biofilm cells, enhances the antimicrobial efficacy of conventional antifungal drugs, and reverses and reduces fungal drug resistance. However, further in vitro and in vivo studies are needed to assess the safety of FOH due to potential adverse effects on immune cells and other factors.

Lee Y, Puumala E, Robbins N, Cowen LE. Antifungal drug resistance: molecular mechanisms in Candida albicans and beyond. Chem Rev. 2021;121(6):3390–411. https://doi.org/10.1021/acs.chemrev.0c00199.CrossRefPubMed

Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis Nature Reviews Disease Primers. 2018;4:18026. https://doi.org/10.1038/nrdp.2018.26.CrossRefPubMed

Vitalis E, Nagy F, Toth Z, et al. Candida biofilm production is associated with higher mortality in patients with candidaemia. Mycoses. 2020;63(4):352–60. https://doi.org/10.1111/myc.13049.CrossRefPubMed

Muderris T, Kaya S, Ormen B, Gokmen AA, Akpinar CV, Gul SY. Mortality and risk factor analysis for Candida blood stream infection: a three-year retrospective study. Journal De Mycologie Medicale. 2020. https://doi.org/10.1016/j.mycmed.2020.101008.CrossRefPubMed

Saghrouni F, Ben Abdeljelil J, Boukadida J, Ben SM. Molecular methods for strain typing of Candida albicans: a review. J Appl Microbiol. 2013;114(6):1559–74. https://doi.org/10.1111/jam.12132.CrossRefPubMed

Rodrigues CF, Černáková L. Farnesol and tyrosol: secondary metabolites with a crucial quorum-sensing role in Candida biofilm development. Genes (Basel). 2020. https://doi.org/10.3390/genes11040444.CrossRefPubMedPubMedCentral

Tian X, Ding H, Ke W, Wang L. Quorum sensing in fungal species. Annu Rev Microbiol. 2021;75:449–69. https://doi.org/10.1146/annurev-micro-060321-045510.CrossRefPubMed

Hornby JM, Jensen EC, Lisec AD, et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol. 2001;67(7):2982–92. https://doi.org/10.1128/AEM.67.7.2982-2992.2001.CrossRefPubMedPubMedCentral

Hornby JM, Kebaara BW, Nickerson KW. Farnesol biosynthesis in Candida albicans: cellular response to sterol inhibition by zaragozic acid b. Antimicrob Agents Chemother. 2003;47(7):2366–9. https://doi.org/10.1128/AAC.47.7.2366-2369.2003.CrossRefPubMedPubMedCentral

10.

Hornby JM, Nickerson KW. Enhanced production of farnesol by Candida albicans treated with four azoles. Antimicrob Agents Chemother. 2004;48(6):2305–7. https://doi.org/10.1128/AAC.48.6.2305-2307.2004.CrossRefPubMedPubMedCentral

11.

Nikoomanesh F, Falahatinejad M, Černáková L, et al. Combination of farnesol with common antifungal drugs: inhibitory effect against Candida species isolated from women with RVVC. Medicina (Kaunas). 2023. https://doi.org/10.3390/medicina59040743.CrossRefPubMed

12.

Nagy F, Toth Z, Daroczi L, et al. Farnesol increases the activity of echinocandins against Candida auris biofilms. Med Mycol. 2020;58(3):404–7. https://doi.org/10.1093/mmy/myz057.CrossRefPubMed

13.

Cernakova L, Dizova S, Gaskova D, Jancikova I, Bujdakova H. Impact of farnesol as a modulator of efflux pumps in a fluconazole-resistant strain of Candida albicans. Microb Drug Resist. 2019;25(6):805–12. https://doi.org/10.1089/mdr.2017.0332.CrossRefPubMed

14.

Fernandes Costa A, Evangelista Araujo D, Santos Cabral M, et al. Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis. Med Mycol. 2019;57(1):52–62. https://doi.org/10.1093/mmy/myx155.CrossRefPubMed

15.

Brilhante RS, de Lima RA, Caetano EP, et al. Effect of farnesol on growth, ergosterol biosynthesis, and cell permeability in Coccidioides posadasii. Antimicrob Agents Chemother. 2013;57(5):2167–70. https://doi.org/10.1128/aac.02457-12.CrossRefPubMedPubMedCentral

16.

Onder S, Oz Y. In vitro effects of farnesol alone and in combination with antifungal drugs against Aspergillus clinical isolates. Med Mycol J. 2021;62(1):5–10. https://doi.org/10.3314/mmj.20-00016.CrossRefPubMed

17.

Cordeiro RA, Teixeira CE, Brilhante RS, et al. Minimum inhibitory concentrations of amphotericin B, azoles and caspofungin against Candida species are reduced by farnesol. Med Mycol. 2013;51(1):53–9. https://doi.org/10.3109/13693786.2012.692489.CrossRefPubMed

18.

Shirtliff ME, Krom BP, Meijering RA, et al. Farnesol-induced apoptosis in Candida albicans. Antimicrob Agents Chemother. 2009;53(6):2392–401. https://doi.org/10.1128/AAC.01551-08.CrossRefPubMedPubMedCentral

19.

Langford ML, Hasim S, Nickerson KW, Atkin AL. Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions. Antimicrob Agents Chemother. 2010;54(2):940–2. https://doi.org/10.1128/AAC.01214-09.CrossRefPubMed

20.

Liu P, Luo L, Guo J, et al. Farnesol induces apoptosis and oxidative stress in the fungal pathogen Penicillium expansum. Mycologia. 2010;102(2):311–8. https://doi.org/10.3852/09-176.CrossRefPubMed

21.

Dinamarco TM, Goldman MH, Goldman GH. Farnesol-induced cell death in the filamentous fungus Aspergillus nidulans. Biochem Soc Trans. 2011;39(5):1544–8. https://doi.org/10.1042/bst0391544.CrossRefPubMed

22.

Wang X, Wang Y, Zhou Y, Wei X. Farnesol induces apoptosis-like cell death in the pathogenic fungus Aspergillus flavus. Mycologia. 2014;106(5):881–8. https://doi.org/10.3852/13-292.CrossRefPubMed

23.

Nagy F, Vitalis E, Jakab A, et al. In vitro and in vivo effect of exogenous farnesol exposure against Candida auris. Frontiers in Microbiology. 2020. https://doi.org/10.3389/fmicb.2020.00957.CrossRefPubMedPubMedCentral

24.

Deveau A, Piispanen AE, Jackson AA, Hogan DA. Farnesol induces hydrogen peroxide resistance in Candida albicans yeast by inhibiting the RAS-cyclic AMP signaling pathway. Eukaryot Cell. 2010;9(4):569–77. https://doi.org/10.1128/EC.00321-09.CrossRefPubMedPubMedCentral

25.

Chen S, Xu Z, Liu S, Duan W, Huang Y, Wei X. A possible mechanism of farnesol tolerance in C. albicans biofilms implemented by activating the PKC signalling pathway and stabilizing ROS levels. J Med Microbiol. 2022. https://doi.org/10.1099/jmm.0.001476.CrossRefPubMed

26.

Heinisch JJ, Rodicio R. Protein kinase c in fungi-more than just cell wall integrity. FEMS Microbiol Rev. 2018. https://doi.org/10.1093/femsre/fux051.CrossRefPubMed

27.

Song J, Zhou J, Zhang L, Li R. Mitochondria-mediated azole drug resistance and fungal pathogenicity: opportunities for therapeutic development. Microorganisms. 2020. https://doi.org/10.3390/microorganisms8101574.CrossRefPubMedPubMedCentral

28.

Pathirana RU, Boone C, Nickerson KW. Longer ubiquinone side chains contribute to enhanced farnesol resistance in yeasts. Microorganisms. 2020. https://doi.org/10.3390/microorganisms8111641.CrossRefPubMedPubMedCentral

29.

Wang FJ, Liu ZH. Systematic analysis of protein expression in Candida albicans exposed to farnesol. Chin Med J (Engl). 2019;132(19):2348–53. https://doi.org/10.1097/CM9.0000000000000420.CrossRefPubMed

30.

Jakab Á, Balla N, Ragyák Á, et al. Transcriptional profiling of the Candida auris response to exogenous farnesol exposure. mSphere. 2021;6(5):e0071021. https://doi.org/10.1128/mSphere.00710-21.CrossRefPubMed

31.

Jin X, Zhang M, Lu J, et al. Hinokitiol chelates intracellular iron to retard fungal growth by disturbing mitochondrial respiration. J Adv Res. 2021;34:65–77. https://doi.org/10.1016/j.jare.2021.06.016.CrossRefPubMedPubMedCentral

32.

Semighini CP, Murray N, Harris SD. Inhibition of Fusarium graminearum growth and development by farnesol. FEMS Microbiol Lett. 2008;279(2):259–64. https://doi.org/10.1111/j.1574-6968.2007.01042.x.CrossRefPubMed

33.

Fairn GD, MacDonald K, McMaster CR. A chemogenomic screen in saccharomyces cerevisiae uncovers a primary role for the mitochondria in farnesol toxicity and its regulation by the Pkc1 pathway. J Biol Chem. 2007;282(7):4868–74. https://doi.org/10.1074/jbc.M610575200.CrossRefPubMed

34.

Egbe NE, Dornelles TO, Paget CM, Castelli LM, Ashe MP. Farnesol inhibits translation to limit growth and filamentation in C. albicans and S. cerevisiae. Microb Cell. 2017;4(9):294–304. https://doi.org/10.15698/mic2017.09.589.CrossRefPubMedPubMedCentral

35.

Ahmad Khan MS, Alshehrei F, Al-Ghamdi SB, Bamaga MA, Al-Thubiani AS, Alam MZ. Virulence and biofilms as promising targets in developing antipathogenic drugs against candidiasis. Future Sci OA. 2020;6(2):FSO440. https://doi.org/10.2144/fsoa-2019-0027.CrossRefPubMedPubMedCentral

36.

Decanis N, Tazi N, Correia A, Vilanova M, Rouabhia M. Farnesol, a fungal quorum-sensing molecule triggers Candida albicans morphological changes by downregulating the expression of different secreted aspartyl proteinase genes. Open Microbiol J. 2011;5:119–26. https://doi.org/10.2174/1874285801105010119.CrossRefPubMedPubMedCentral

37.

Nikoomanesh F, Roudbarmohammadi S, Khoobi M, Haghighi F, Roudbary M. Design and synthesis of mucoadhesive nanogel containing farnesol: investigation of the effect on HWP1, SAP6 and Rim101 genes expression of Candida albicans in vitro. Artif Cells Nanomed Biotechnol. 2019;47(1):64–72. https://doi.org/10.1080/21691401.2018.1543193.CrossRefPubMed

38.

Sharma M, Prasad R. The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by abc multidrug transporters and synergizes with drugs in Candida albicans. Antimicrob Agents Chemother. 2011;55(10):4834–43. https://doi.org/10.1128/AAC.00344-11.CrossRefPubMedPubMedCentral

39.

Jabra-Rizk MA, Shirtliff M, James C, Meiller T. Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance. FEMS Yeast Res. 2006;6(7):1063–73. https://doi.org/10.1111/j.1567-1364.2006.00121.x.CrossRefPubMed

40.

Dekkerová J, Černáková L, Kendra S, et al. Farnesol boosts the antifungal effect of fluconazole and modulates resistance in Candida auris through regulation of the CDR1 and ERG11 genes. J Fungi (Basel). 2022. https://doi.org/10.3390/jof8080783.CrossRefPubMed

41.

Cordeiro RD, Nogueira GC, Brilhante RSN, et al. Farnesol inhibits in vitro growth of the cryptococcus neoformans species complex with no significant changes in virulence-related exoenzymes. Vet Microbiol. 2012;159(3–4):375–80. https://doi.org/10.1016/j.vetmic.2012.04.008.CrossRefPubMed

42.

Cordeiro RA, Pereira LMG, de Sousa JK, et al. Farnesol inhibits planktonic cells and antifungal-tolerant biofilms of trichosporon asahii and trichosporon inkin. Med Mycol. 2019;57(8):1038–45. https://doi.org/10.1093/mmy/myy160.CrossRefPubMed

43.

Derengowski LS, De-Souza-Silva C, Braz SV, et al. Antimicrobial effect of farnesol, a Candida albicans quorum sensing molecule, on paracoccidioides brasiliensis growth and morphogenesis. Ann Clin Microbiol Antimicrob. 2009;8:13. https://doi.org/10.1186/1476-0711-8-13.CrossRefPubMedPubMedCentral

44.

Pumeesat P, Wongsuk T, Muangkaew W, Luplertlop N. Growth-inhibitory effects of farnesol against Scedosporium boydii and Lomentospora prolificans. Southeast Asian J Trop Med Public Health. 2017;48(1):170–8.PubMed

45.

Kischkel B, Souza GK, Chiavelli LUR, Pomini AM, Svidzinski TIE, Negri M. The ability of farnesol to prevent adhesion and disrupt Fusarium keratoplasticum biofilm. Appl Microbiol Biotechnol. 2020;104(1):377–89. https://doi.org/10.1007/s00253-019-10233-2.CrossRefPubMed

46.

Brilhante RSN, Pereira VS, Nobre AFD, et al. Exogenous fungal quorum sensing molecules inhibit planktonic cell growth and modulate filamentation and biofilm formation in the Sporothrix schenckii complex. Biofouling. 2020;36(8):909–21. https://doi.org/10.1080/08927014.2020.1828373.CrossRefPubMed

47.

Lohse MB, Gulati M, Johnson AD, Nobile CJ. Development and regulation of single- and multi-species Candida albicans biofilms. Nat Rev Microbiol. 2018;16(1):19–31. https://doi.org/10.1038/nrmicro.2017.107.CrossRefPubMed

48.

Dizova S, Bujdakova H. Properties and role of the quorum sensing molecule farnesol in relation to the yeast Candida albicans. Pharmazie. 2017;72(6):307–12. https://doi.org/10.1691/ph.2017.6174.CrossRefPubMed

49.

Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol. 2002;68(11):5459–63. https://doi.org/10.1128/AEM.68.11.5459-5463.2002.CrossRefPubMedPubMedCentral

50.

Sachivkina N, Podoprigora I, Bokov D. Morphological characteristics of Candida albicans, Candida krusei, Candida guilliermondii, and Candida glabrata biofilms, and response to farnesol. Vet World. 2021;14(6):1608–14. https://doi.org/10.14202/vetworld.2021.1608-1614.CrossRefPubMedPubMedCentral

51.

Zibafar E, Hashemi SJ, Zaini F, Zeraati H, Rezaie S, Kordbacheh P. Inhibitory effect of farnesol on biofilm formation by Candida tropicalis. Daru-Journal of Pharmaceutical Sciences. 2009;17(1):19–23.

52.

Sebaa S, Boucherit-Otmani Z, Courtois P. Effects of tyrosol and farnesol on Candida albicans biofilm. Mol Med Rep. 2019;19(4):3201–9. https://doi.org/10.3892/mmr.2019.9981.CrossRefPubMedPubMedCentral

53.

Luo AH, Wang F, Sun DG, Liu XY, Xin BC. Formation, development, and cross-species interactions in biofilms. Frontiers in Microbiology. 2022. https://doi.org/10.3389/fmicb.2021.757327.CrossRefPubMedPubMedCentral

54.

Yılmaz Öztürk B, Yenice Gürsu B, Dağ İ. In vitro effect of farnesol on planktonic cells and dual biofilm formed by Candida albicans and Escherichia coli. Biofouling. 2022;38(4):355–66. https://doi.org/10.1080/08927014.2022.2066530.CrossRefPubMed

55.

Fernandes RA, Monteiro DR, Arias LS, Fernandes GL, Delbem AC, Barbosa DB. Biofilm formation by Candida albicans and streptococcus mutans in the presence of farnesol: a quantitative evaluation. Biofouling. 2016;32(3):329–38. https://doi.org/10.1080/08927014.2016.1144053.CrossRefPubMed

56.

Monteiro DR, Arias LS, Fernandes RA, et al. Antifungal activity of tyrosol and farnesol used in combination against Candida species in the planktonic state or forming biofilms. J Appl Microbiol. 2017;123(2):392–400. https://doi.org/10.1111/jam.13513.CrossRefPubMed

57.

Gaálová-Radochová B, Kendra S, Jordao L, et al. Effect of quorum sensing molecule farnesol on mixed biofilms of Candida albicans and Staphylococcus aureus. Antibiotics (Basel). 2023. https://doi.org/10.3390/antibiotics12030441.CrossRefPubMed

58.

Wang X, He H, Liu J, Xie S, Han J. Inhibiting roles of farnesol and hog in morphological switching of Candida albicans. Am J Transl Res. 2020;12(11):6988–7001.PubMedPubMedCentral

59.

Nickerson KW, Atkin AL. Deciphering fungal dimorphism: farnesol’s unanswered questions. Mol Microbiol. 2017;103(4):567–75. https://doi.org/10.1111/mmi.13601.CrossRefPubMed

60.

Chen S, Xia J, Li C, Zuo L, Wei X. The possible molecular mechanisms of farnesol on the antifungal resistance of C. albicans biofilms: the regulation of CYR1 and PDE2. BMC Microbiol. 2018;18(1):203. https://doi.org/10.1186/s12866-018-1344-z.CrossRefPubMedPubMedCentral

61.

Lorek J, Poggeler S, Weide MR, Breves R, Bockmuhl DP. Influence of farnesol on the morphogenesis of Aspergillus niger. J Basic Microbiol. 2008;48(2):99–103. https://doi.org/10.1002/jobm.200700292.CrossRefPubMed

62.

Fan Y, He H, Dong Y, Pan H. Hyphae-specific genes HGC1, ALS3, HWP1, and ECE1 and relevant signaling pathways in Candida albicans. Mycopathologia. 2013;176(5–6):329–35. https://doi.org/10.1007/s11046-013-9684-6.CrossRefPubMed

63.

Cao YY, Cao YB, Xu Z, et al. Cdna microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. Antimicrob Agents Chemother. 2005;49(2):584–9. https://doi.org/10.1128/AAC.49.2.584-589.2005.CrossRefPubMedPubMedCentral

64.

Katragkou A, McCarthy M, Alexander EL, et al. In vitro interactions between farnesol and fluconazole, amphotericin b or micafungin against Candida albicans biofilms. J Antimicrob Chemother. 2015;70(2):470–8. https://doi.org/10.1093/jac/dku374.CrossRefPubMed

65.

Xia J, Qian F, Xu W, Zhang Z, Wei X. In vitro inhibitory effects of farnesol and interactions between farnesol and antifungals against biofilms of Candida albicans resistant strains. Biofouling. 2017;33(4):283–93. https://doi.org/10.1080/08927014.2017.1295304.CrossRefPubMed

66.

Kovács R, Bozó A, Gesztelyi R, et al. Effect of caspofungin and micafungin in combination with farnesol against Candida parapsilosis biofilms. Int J Antimicrob Agents. 2016;47(4):304–10. https://doi.org/10.1016/j.ijantimicag.2016.01.007.CrossRefPubMed

67.

Fernández-Rivero ME, Del Pozo JL, Valentín A, de Diego AM, Pemán J, Cantón E. Activity of amphotericin b and anidulafungin combined with rifampicin, clarithromycin, ethylenediaminetetraacetic acid, n-acetylcysteine, and farnesol against Candida tropicalis biofilms. J Fungi (Basel). 2017. https://doi.org/10.3390/jof3010016.CrossRefPubMed

68.

Yu LH, Wei X, Ma M, Chen XJ, Xu SB. Possible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm. Antimicrob Agents Chemother. 2012;56(2):770–5. https://doi.org/10.1128/AAC.05290-11.CrossRefPubMedPubMedCentral

69.

Dizova S, Cernakova L, Bujdakova H. The impact of farnesol in combination with fluconazole on Candida albicans biofilm: regulation of ERG20, ERG9, and ERG11 genes. Folia Microbiol (Praha). 2018;63(3):363–71. https://doi.org/10.1007/s12223-017-0574-z.CrossRefPubMed

70.

Berman J, Krysan DJ. Drug resistance and tolerance in fungi. Nat Rev Microbiol. 2020;18(6):319–31. https://doi.org/10.1038/s41579-019-0322-2.CrossRefPubMedPubMedCentral

71.

Dumitru R, Hornby JM, Nickerson KW. Defined anaerobic growth medium for studying Candida albicans basic biology and resistance to eight antifungal drugs. Antimicrob Agents Chemother. 2004;48(7):2350–4. https://doi.org/10.1128/aac.48.7.2350-2354.2004.CrossRefPubMedPubMedCentral

72.

Roudbary M, Vahedi-Shahandashti R, dos Santos ALS, et al. Biofilm formation in clinically relevant filamentous fungi: a therapeutic challenge. Crit Rev Microbiol. 2022;48(2):197–221. https://doi.org/10.1080/1040841x.2021.1950121.CrossRefPubMed

73.

Uppuluri P, Zaldivar MA, Anderson MZ, et al. Candida albicans dispersed cells are developmentally distinct from biofilm and planktonic cells. Mbio. 2018. https://doi.org/10.1128/mBio.01338-18.CrossRefPubMedPubMedCentral

74.

Rossignol T, Logue ME, Reynolds K, Grenon M, Lowndes NF, Butler G. Transcriptional response of Candida parapsilosis following exposure to farnesol. Antimicrob Agents Chemother. 2007;51(7):2304–12. https://doi.org/10.1128/AAC.01438-06.CrossRefPubMedPubMedCentral

75.

Liu Z, Rossi JM, Myers LC. Candida albicans Zn cluster transcription factors Tac1 and Znc1 are activated by farnesol to upregulate a transcriptional program including the multidrug efflux pump Cdr1. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/aac.00968-18.CrossRefPubMedPubMedCentral

76.

Zhu JS, Krom BP, Sanglard D, et al. Farnesol-induced apoptosis in Candida albicans is mediated by Cdr1-p extrusion and depletion of intracellular glutathione. Plos One. 2011. https://doi.org/10.1371/journal.pone.0028830.CrossRefPubMedPubMedCentral

77.

Mahendrarajan V, Bari VK. A critical role of farnesol in the modulation of amphotericin B and aureobasidin A antifungal drug susceptibility. Mycology. 2022;13(4):305–17. https://doi.org/10.1080/21501203.2022.2138599.CrossRefPubMedPubMedCentral

78.

Singkum P, Muangkaew W, Suwanmanee S, Pumeesat P, Wongsuk T, Luplertlop N. Suppression of the pathogenicity of Candida albicans by the quorum-sensing molecules farnesol and tryptophol. J Gen Appl Microbiol. 2020;65(6):277–83. https://doi.org/10.2323/jgam.2018.12.002.CrossRefPubMed

79.

Nickerson KW, Atkin AL, Hornby JM. Quorum sensing in dimorphic fungi: farnesol and beyond. Appl Environ Microbiol. 2006;72(6):3805–13. https://doi.org/10.1128/AEM.02765-05.CrossRefPubMedPubMedCentral

80.

Černáková L, Jordao L, Bujdáková H. Impact of farnesol and Corsodyl(®) on Candida albicans forming dual biofilm with streptococcus mutans. Oral Dis. 2018;24(6):1126–31. https://doi.org/10.1111/odi.12873.CrossRefPubMed

81.

Hisajima T, Maruyama N, Tanabe Y, et al. Protective effects of farnesol against oral candidiasis in mice. Microbiol Immunol. 2008;52(7):327–33. https://doi.org/10.1111/j.1348-0421.2008.00044.x.CrossRefPubMed

82.

Li C, Xu Z, Liu S, Huang R, Duan W, Wei X. In vivo antifungal activities of farnesol combined with antifungal drugs against murine oral mucosal candidiasis. Biofouling. 2021;37(8):818–29. https://doi.org/10.1080/08927014.2021.1967938.CrossRefPubMed

83.

Bozo A, Doman M, Majoros L, Kardos G, Varga I, Kovacs R. The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model. J Microbiol. 2016;54(11):753–60. https://doi.org/10.1007/s12275-016-6298-y.CrossRefPubMed

84.

Sachivkina N, Senyagin A, Podoprigora I, et al. Enhancement of the antifungal activity of some antimycotics by farnesol and reduction of Candida albicans pathogenicity in a quail model experiment. Vet World. 2022;15(4):848–54. https://doi.org/10.14202/vetworld.2022.848-854.CrossRefPubMedPubMedCentral

85.

Navarathna DH, Hornby JM, Krishnan N, Parkhurst A, Duhamel GE, Nickerson KW. Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans. Infect Immun. 2007;75(4):1609–18. https://doi.org/10.1128/iai.01182-06.CrossRefPubMedPubMedCentral

86.

Hargarten JC, Moore TC, Petro TM, Nickerson KW, Atkin AL. Candida albicans quorum sensing molecules stimulate mouse macrophage migration. Infect Immun. 2015;83(10):3857–64. https://doi.org/10.1128/iai.00886-15.CrossRefPubMedPubMedCentral

87.

Jung YY, Hwang ST, Sethi G, Fan L, Arfuso F, Ahn KS. Potential anti-inflammatory and anti-cancer properties of farnesol. Molecules. 2018. https://doi.org/10.3390/molecules23112827.CrossRefPubMedPubMedCentral

88.

Zhang Y, Long Y, Yu S, et al. Natural volatile oils derived from herbal medicines: a promising therapy way for treating depressive disorder. Pharmacol Res. 2021;164:105376. https://doi.org/10.1016/j.phrs.2020.105376.CrossRefPubMed

89.

Katsuyama M, Kobayashi Y, Ichikawa H, et al. A novel method to control the balance of skin microflora part 2. A study to assess the effect of a cream containing farnesol and xylitol on atopic dry skin. J Dermatol Sci. 2005;38(3):207–13. https://doi.org/10.1016/j.jdermsci.2005.01.003.CrossRefPubMed

90.

Chang WQ, Li Y, Zhang L, Cheng AX, Lou HX. Retigeric acid b attenuates the virulence of Candida albicans via inhibiting adenylyl cyclase activity targeted by enhanced farnesol production. PLoS ONE. 2012;7(7):10. https://doi.org/10.1371/journal.pone.0041624.CrossRefPubMedCentral

91.

Singh BN, Upreti DK, Singh BR, et al. Quercetin sensitizes fluconazole-resistant Candida albicans to induce apoptotic cell death by modulating quorum sensing. Antimicrob Agents Chemother. 2015;59(4):2153–68. https://doi.org/10.1128/aac.03599-14.CrossRefPubMedPubMedCentral

92.

Li Y, Chen C, Cong L, et al. Inhibitory effects of a maleimide compound on the virulence factors of Candida albicans. Virulence. 2023;14(1):2230009. https://doi.org/10.1080/21505594.2023.2230009.CrossRefPubMedPubMedCentral

93.

Yan Y, Tan F, Miao H, Wang H, Cao Y. Effect of shikonin against Candida albicans biofilms. Front Microbiol. 2019;10:1085. https://doi.org/10.3389/fmicb.2019.01085.CrossRefPubMedPubMedCentral

94.

Li Y, Shan MZ, Yan MJ, et al. The inhibition of trans-cinnamaldehyde on the virulence of Candida albicans via enhancing farnesol secretion with low potential for the development of resistance. Biochem Biophys Res Commun. 2019;515(4):544–50. https://doi.org/10.1016/j.bbrc.2019.05.165.CrossRef

95.

Li Y, Shan M, Yan M, et al. Anticandidal activity of kalopanaxsaponin A: effect on proliferation, cell morphology, and key virulence attributes of Candida albicans. Front Microbiol. 2019;10:2844. https://doi.org/10.3389/fmicb.2019.02844.CrossRefPubMedPubMedCentral

96.

Zhang L, Chang W, Sun B, Groh M, Speicher A, Lou H. Bisbibenzyls, a new type of antifungal agent, inhibit morphogenesis switch and biofilm formation through upregulation of DPP3 in Candida albicans. PLoS ONE. 2011;6(12):e28953. https://doi.org/10.1371/journal.pone.0028953.CrossRefPubMedPubMedCentral

97.

Lee JH, Kim YG, Khadke SK, Lee J. Antibiofilm and antifungal activities of medium-chain fatty acids against Candida albicans via mimicking of the quorum-sensing molecule farnesol. Microb Biotechnol. 2021;14(4):1353–66. https://doi.org/10.1111/1751-7915.13710.CrossRefPubMed

98.

Su H, Han L, Ding N, Guan P, Hu C, Huang X. Bafilomycin C1 exert antifungal effect through disturbing sterol biosynthesis in Candida albicans. J Antibiot (Tokyo). 2018;71(4):467–76. https://doi.org/10.1038/s41429-017-0009-8.CrossRefPubMed

99.

Liu RH, Shang ZC, Li TX, Yang MH, Kong LY. In vitro antibiofilm activity of eucarobustol E against Candida albicans. Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/aac.02707-16.CrossRefPubMedPubMedCentral

100.

Unnanuntana A, Bonsignore L, Shirtliff ME, Greenfield EM. The effects of farnesol on Staphylococcus aureus biofilms and osteoblasts. An in vitro study. J Bone Joint Surg Am. 2009;91(11):2683–92. https://doi.org/10.2106/JBJS.H.01699.CrossRefPubMedPubMedCentral

101.

Abe S, Tsunashima R, Iijima R, et al. Suppression of anti-Candida activity of macrophages by a quorum-sensing molecule, farnesol, through induction of oxidative stress. Microbiol Immunol. 2009;53(6):323–30. https://doi.org/10.1111/j.1348-0421.2009.00128.x.CrossRefPubMed

102.

Vivas W, Leonhardt I, Hunniger K, Hader A, Marolda A, Kurzai O. Multiple signaling pathways involved in human dendritic cell maturation are affected by the fungal quorum-sensing molecule farnesol. J Immunol. 2019;203(11):2959–69. https://doi.org/10.4049/jimmunol.1900431.CrossRefPubMed

103.

Han Y, Zhang Y, Zeng W, et al. Synergy with farnesol rejuvenates colistin activity against colistin-resistant gram-negative bacteria in vitro and in vivo. Int J Antimicrob Agents. 2023;62(3):106899. https://doi.org/10.1016/j.ijantimicag.2023.106899.CrossRefPubMed

104.

Joo JH, Jetten AM. Molecular mechanisms involved in farnesol-induced apoptosis. Cancer Lett. 2010;287(2):123–35. https://doi.org/10.1016/j.canlet.2009.05.015.CrossRefPubMed

Title: Exploring the Potential of Farnesol as a Novel Antifungal Drug and Related Challenges
Authors: Dongming Zheng
Linlan Yang
Yuxin Bai
Jiangyan Yong
Yan Li
Publication date: 26-02-2024
Publisher: Springer US
Keywords: Fluconazole
Amphotericin B
Itraconazole
Published in: Current Infectious Disease Reports / Issue 4/2024
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-024-00839-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com